Loading...

BLCO - Bausch + Lomb Corporation

Analyst Coverage Initiated Signal for 06-24-2022
Analyst Coverage Initiated: BLCO rating Outperform by Evercore ISI
Price Target: $21


Loading Chart BLCO

Stock Signal Information


Signal

Analyst Coverage Initiated: BLCO rating Outperform by Evercore ISI
Price Target: $21
Report Date: 06-24-2022
Symbol: BLCO - Bausch + Lomb Corporation
Sector: Healthcare
Industry: Medical Instruments & Supplies
Analyst Coverage Initiated: BLCO rating Outperform by Evercore ISI
Price Target: $21

  BLCO Technical Analysis

Company Contact

Bausch + Lomb Corporation (BLCO)
520 Applewood Crescent
Vaughan, ON L4K 4B4
Phone: 905-695-7700
Website: https://www.bausch.com
CEO:

BLCO, Bausch + Lomb Corporation

BLCO Bausch + Lomb Corporation Logo Image

NYSE, New York Stock Exchange


Company Profile

Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments and treatments for various eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases; and and contact lenses for therapeutic use. The Surgical segment provides medical device equipment, consumables, and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions. The company was founded in 1853 and is headquartered in Vaughan, Canada.